---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-047742"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T03:05:44.208754+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Benitec Q2 FY2026 net loss $11.8M; all Cohort 1 patients respond to BB-301 at 12 months

## Summary
- Net loss of $11.8M ($0.26 per share) vs $9.6M YoY; total expenses $13.4M (up from $10.8M).
- All 4 Cohort 1 completers in BB-301 Phase 1b/2a met Responder criteria at 12-month follow-up.
- Patient 1 showed deepening improvements in swallow function and dysphagia at 24 months.
- Cash and equivalents $189M; FDA meeting mid-2026 to confirm pivotal study design for BB-301.
- Cohort 2 interim results expected mid-2026; first patient dosed in Q4 2025.

## SEC filing metadata
- accession: 0001193125-26-047742
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312526047742/0001193125-26-047742-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312526047742/bntc-20260212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-047742
- JSON: https://secwatch.observer/filing/0001193125-26-047742.json
- Plain text: https://secwatch.observer/filing/0001193125-26-047742.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.